Aviation Medication Transparency Act of 2026

What it does

• •Requires the FAA Administrator to publish and maintain a publicly accessible website listing medications approved for use by airmen and air traffic control specialists seeking medical certification or clearance.
• •The list must include approved prescription and over-the-counter medications, contraindications, conditions requiring FAA review, and medications designated as 'Do Not Issue' or 'Do Not Fly.'
• •Mandates the list be made user-friendly, accessible via MedXPress during initial medical certification applications, and updated when relevant FAA medical certification policies change.
• •Requires the FAA to consult with pilot unions, air traffic controller representatives, aviation schools, medical associations, and other stakeholders before publishing the list.

Why it matters

• •The list aims to provide aviation stakeholders transparent, accessible information about which medications are safe for aviation use, reducing confusion about medical certification requirements.
• •Standardized, publicly available guidance helps airmen, air traffic controllers, and medical providers make informed decisions about medications without unnecessary delays in certification processes.
• •A liability provision protects the FAA from responsibility if users experience adverse reactions or certification denials based on reliance on the published list.

Who is affected

• •Airmen and air traffic control specialists applying for or maintaining medical certification or clearance.
• •Aviation medical examiners, doctors, and medical providers treating aviation professionals.
• •Flight training schools, airlines, pilot unions, and general aviation operators.

What happens next

The FAA Administrator must publish the medication list on a public website within one year of the Act's enactment, with updates made at least annually or when relevant medical certification policies change.